Thrombophob

As directed by your Phsician

Slight fever, headache, chills, nausea, vomiting, constipation, epistaxis, bruising, slight haematuria, skin necrosis (SC inj), osteoporosis, alopecia. Hypersensitivity reactions include urticaria, conjunctivitis, rhinitis, asthma, angioedema and anaphylactic shock. Priapism.

Potentially Fatal: Heparin-induced thrombocytopenia with or without thrombosis; bleeding.

Thrombocytopenia

Thrombocytopenia has been reported to occur in patients receiving Heparin with a reported incidence of 0 to 30%. Platelet counts should be obtained at baseline and periodically during Heparin administration. Mild thrombocytopenia (count greater than 100,000/mm3) may remain stable or reverse even if Heparin is continued. However, thrombocytopenia of any degree should be monitored closely. If the count falls below 100,000/mm3 or if recurrent thrombosis develops, the Heparin product should be discontinued, and if necessary, an alternative anticoagulant administered.

Delayed Onset of HIT and HITT

Heparin-induced Thrombocytopenia and Heparin-induced Thrombocytopenia and Thrombosis can occur up to several weeks after the discontinuation of Heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of Heparin should be evaluated for HIT and HITT.

Use in Neonates

Carefully examine all Heparin Sodium Injection vials and cartridges to confirm choice of the correct strength prior to administration of the drug. Pediatric patients, including neonates, have died as a result of medication errors in which Heparin Sodium Injection vials have been confused with “catheter lock flush” vials.

Heparin Resistance

Increased resistance to Heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer, and in postsurgical patients.

Increased Risk to Older Patients, Especially Women

A higher incidence of bleeding has been reported in patients, particularly women over 60 years of age.

Monitor platelet counts. Discontinue treatment if thrombocytopenia occurs. Hypersensitivity, elderly, pregnancy.

Patients predisposed to active bleeding including thrombocytopenia, peptic ulcer disease, cerebrovascular disorders, haemorrhagic blood disorders, bacterial endocarditis, severe hypertension, oesophageal varices. Recent surgery at sites where haemorrhage would be an especial risk. Severe renal and hepatic impairment. Cerebral or subarachnoid haemorrhage, abdominal or thoracic bleeding into closed space, severe traumatic bleed, hepatic, renal, splenic or arterial injury, severe haemostatic defect, arterial thrombosis with heparin-associated thrombocytopenia. IM admin.

Pregnancy- Caution when used during pregnancy.

Lactation- Not excreted in breast milk

Geriatic- Higher incidence of bleeding in women older than 60 years of age.

Inhibited by zinc. Antiplatelet drugs e.g. aspirin and dipyridamole may precipitate bleeding.

Potentially Fatal: NSAIDs may increase risk of haemorrhage. Effect increased by dextrans, high doses of penicillin and cephalosporins, phenylbutazone, asparaginase. streptokinase and some contrast media.

–

Intravenous
Store at 15-30°C

Subcutaneous
Store at 15-30°C

–

http://www.drugsupdate.com/brand/generic/Heparin/32945

https://www.1mg.com/drugs/thrombophob-ointment-12683

https://www.mims.com/india/drug/info/heparin/

https://en.wikipedia.org/wiki/Cadila_Healthcare

https://www.medindia.net/drug-price/heparin/thrombophob-inj.htm